Business:
RNA Editing Therapeutics
Drug notes:
Also RD undisclosed
About:
AIRNA Bio is developing oligonucleotide-based therapeutics that mediate RNA editing for patients with rare and common diseases. AIRNA uses a unique oligonucleotide drug construct to bind to a specific RNA sequence and then attract endogenous ADAR enzymes to the RNA. ADAR enzymes can mediate the chemical transformation of a specific adenosine (A) to inosine (I), which is read as guanosine (G) when translating RNA to protein. This A-to-I edit can fix pathogenic point mutations, induce therapeutically-effective gain-of-function or loss-of-function mutations, or change protein conformation.
Research Associate / Senior Research Associate, Pr... Cambridge, MA|42 days ago
Director, Oligonucleotide Synthesis and Technology... Tübingen, Baden-Württemberg, Germany|69 days ago
Clinical Scientist United Kingdom|71 days ago
Principal Scientist, Biomarker Lead Cambridge, MA|71 days ago
Associate Director, Drug Product Cambridge, MA|Posting date unknown
Vice President, Portfolio Strategy Cambridge, MA|Posting date unknown
Research Associate, Oligonucleotide Chemistry Tübingen, Baden-Württemberg, Germany|Posting date unknown